CSL Highlights Gum Disease Vaccine Partnership With Sanofi Pasteur, Cardio Drug, During R&D Update
This article was originally published in The Pink Sheet Daily
Executive Summary
Research suggests periodontal disease leads to systemic threats, including cardiovascular disease, oropharyngeal and pancreatic cancers and diabetes, expert says.
You may also be interested in...
Australia's TGA Clears CSL's H1N1 Vaccine For Young Children
Australia's Therapeutic Goods Administration has approved CSL's Panvax H1N1 flu vaccine for children between three years old and 10 years old
Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With Australia's CSL
Merck took its time coming back into the flu vaccine field, but the expansion of world suppliers of vaccines brought a very well-suited partner to its doorstep
CSL Reports Profits Up 63 Percent for FY 2009; Swine Flu Data Expected Next Month
PERTH, Australia - Melbourne-headquartered CSL reported this week that it posted AU$1.15 billion ($943 million) in net profits for FY2009, up 63 percent year on year. With cash flow from operations of AU$1.03 billion, the company is well positioned for an alternative acquisition target after scuttling its $3.1 billion merger with U.S.-based Talecris